 HIGH POINT, N.C. and WESTON, Fla., June 22, 2021 GLOBE NEWSWIRE -- vTv Therapeutics Inc. vTv, Nasdaq:VTVT and Cantex Pharmaceuticals, Inc. Cantex today announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTvs novel antagonist of RAGE the receptor for advanced glycation endproducts. 